Long-term Safety of Sonelokimab in Psoriatic Arthritis Patients
Tests sonelokimab, an injected drug, in adults with psoriatic arthritis who finished earlier studies.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
Key facts
- Where
- Avon Park, Avondale, Baytown, Charlotte, Clearwater, Duncansville, Jonesboro, Leland, Lubbock, Memphis, Mesa, Middleburg Heights, Phoenix, Scottsdale, Tampa, Tucson, and Upland, United StatesSee the 17 sites
- Phase
- Phase 3
Where in United States
- Avon ParkAvon Park, United StatesNo longer taking part
- AvondaleAvondale, United StatesNo longer taking part
- BaytownBaytown, United StatesNo longer taking part
- CharlotteCharlotte, United StatesNo longer taking part
- ClearwaterClearwater, United StatesNo longer taking part
- DuncansvilleDuncansville, United StatesNo longer taking part
- JonesboroJonesboro, United StatesNo longer taking part
- LelandLeland, United StatesNo longer taking part
- LubbockLubbock, United StatesNo longer taking part
- MemphisMemphis, United StatesNo longer taking part
- MesaMesa, United StatesNo longer taking part
- Middleburg HeightsMiddleburg Heights, United StatesNo longer taking part
- PhoenixPhoenix, United StatesNo longer taking part
- ScottsdaleScottsdale, United StatesNo longer taking part
- TampaTampa, United StatesNo longer taking part
- TucsonTucson, United StatesNo longer taking part
- UplandUpland, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- MoonLake Immunotherapeutics AG
- Trial code
- NCT07223138
- Record updated
- 9 September 2026
- Original description
This is a study to demonstrate the long-term safety, tolerability and clinical efficacy of sonelokimab in the treatment of patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302)Read full original descriptionShow less
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
This is a study to demonstrate the long-term safety, tolerability and clinical efficacy of sonelokimab in the treatment of patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302)
Inclusion: Participants who, in the opinion of the investigator, are expected to benefit from participation in this OLE study; Participants who have received the second to last and/or last dose, as planned in the parental study, and have completed the end-of-treatment visit of the parental study; Participants must have received their last dose of study treatment in the parental study no more than 8 weeks (but ideally 4 weeks) before the first dose in this OLE study; Female participants are eligible to participate if they are not pregnant or breastfeeding and must be of nonchildbearing potential or must agree to use highly effective methods of contraception during the study and for at least 8 weeks after the last dose of study treatment. Female participant of childbearing potential must refrain from donating oocytes during the study and for at least 8 weeks after the last dose of study treatment; Male participants must be willing to use a condom when sexually active with a partner of childbearing potential during the study and for at least 8 weeks after the last dose of study treatment, unless surgically sterile. Male participants must also agree to refrain from donating sperm during the study and for at least 8 weeks after the last dose of study treatment.
Exclusion: Participants who plan to participate in another interventional study for a drug or device during this study; Participants who met any of the discontinuation criteria of the parental study at the time of enrollment in this OLE study; Participants who have ongoing or planned use of one or more of the prohibited PsA or non-PsA treatments specified in this protocol; Participants who were unblinded during the parental study; Participant noncompliance to the parental study.